Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Knoxville, TN

    Search
    Knoxville, TN
    Show Map
    Map View
    Knoxville, TN

    Popular Searches

    By Condition

    Depression Clinical Trials in Tennessee

    Anxiety Clinical Trials in Tennessee

    Schizophrenia Clinical Trials in Tennessee

    ADHD Clinical Trials in Tennessee

    Bipolar Disorder Clinical Trials in Tennessee

    Multiple Sclerosis Clinical Trials in Tennessee

    Autism Clinical Trials in Tennessee

    Treatment Resistant Depression Clinical Trials in Tennessee

    Borderline Personality Disorder Clinical Trials in Tennessee

    Social Anxiety Disorder Clinical Trials in Tennessee

    Parkinson's Disease Clinical Trials in Tennessee

    Alzheimer's Disease Clinical Trials in Tennessee

    By Location

    Clinical Trials near Nashville, TN

    Clinical Trials near Memphis, TN

    Clinical Trials near Knoxville, TN

    Clinical Trials near Chattanooga, TN

    Clinical Trials near Germantown, TN

    Clinical Trials near Kingsport, TN

    Clinical Trials near Jackson, TN

    Clinical Trials near Bristol, TN

    Clinical Trials near Johnson City, TN

    Clinical Trials near Franklin, TN

    Clinical Trials near Cordova, TN

    Clinical Trials near Murfreesboro, TN

    Other People Viewed

    By Subject

    213 Clinical Trials near Knoxville, TN

    16 Multiple Sclerosis Trials near Knoxville, TN

    Top Clinical Trials near Jackson, TN

    Top Clinical Trials near Hendersonville, TN

    Top Clinical Trials near Germantown, TN

    Top Clinical Trials near Gallatin, TN

    Top Clinical Trials near Goodlettsville, TN

    Top Clinical Trials near Dickson, TN

    Top Clinical Trials near Cordova, TN

    Top Clinical Trials near Crossville, TN

    Top Clinical Trials near Chattanooga, TN

    Top Clinical Trials near Brentwood, TN

    By Trial

    ANNE One-Wellue Device for Vital Sign Monitoring

    Obicetrapib for Antioxidant Deficiency

    Gene Therapy for Developmental Encephalopathy

    Optune Device for Meningioma

    Collaborative Care for Substance Use and Mental Health Disorders

    Rituximab + LMP-Specific T-Cells for Post-transplant Lymphoproliferative Disease

    Bicalutamide + BCG for Bladder Cancer

    Medication Reduction for Aging

    Aromatherapy for Pain and Nausea in Acute Care Therapy

    Mind-Body Balance for Pediatric Migraine

    FITC-E2 CAR T Cells + Folate-Fluorescein for Osteosarcoma

    Bone Graft for Wound Healing

    Related Searches

    Top Substance-abuse Clinical Trials

    Top Perimenopause Clinical Trials

    Top Me-cfs Clinical Trials

    Top Weight-gain Clinical Trials

    Opioid-Free Pain Management for Scoliosis

    Losartan for Cystic Fibrosis

    Baricitinib for Rheumatoid Arthritis

    MEGO Therapy for Acute Myeloid Leukemia

    Urolithin A for Healthy Adults

    Photobiomodulation for Temporomandibular Disorder Pain

    Cannabis for Chronic Headaches

    Stem Cell Therapy for Chronic and Acute Conditions

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      148 Clinical Paid Trials near Knoxville, TN

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Strategic and Interactive Signing Instruction for Teacher Practice

      Knoxville, Tennessee
      A training given to teachers will include reviewing the intervention manual, live modeling, and discussing intervention fidelity. The PI and a rater will use the Strategic and Interactive Signing Instruction. fidelity checklist to rate teacher faithfulness to each component of Strategic and Interactive Signing Instruction. across a session. Frequency and doses of additional training (e.g., coaching) will be documented in order to track procedures that effectively increase teacher faithfulness to implementation of Strategic and Interactive Signing Instruction.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Not Teachers Of The Deaf

      4 Participants Needed

      Cleerly CAD Staging System for Preventing Heart Disease

      Knoxville, Tennessee
      TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:55+

      Key Eligibility Criteria

      Disqualifiers:Symptomatic CVD, Kidney Disease, Thyroid Cancer, Others

      7500 Participants Needed

      Robotic vs Open Surgery for Ventral Hernia

      Knoxville, Tennessee
      This trial compares two types of surgeries for fixing abdominal wall hernias: traditional open surgery and robotic-assisted surgery. It aims to see if robotic surgery can shorten the hospital stay compared to open surgery. Patients with ventral hernias will undergo one of the two methods, and their recovery will be evaluated. Robotic-assisted surgery has been increasingly used in recent years for ventral hernia repair, combining minimally invasive techniques with retromuscular mesh placement.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Age Under 18, Pregnancy, Prisoners, Others

      200 Participants Needed

      Reduced-Calorie Diet for Obesity

      Knoxville, Tennessee
      For weight loss to occur, energy intake needs to be reduced to incur an energy deficit. One dietary strategy that may facilitate reducing energy intake and enhancing weight loss is consuming a diet low in dietary energy density (ED). The ED of a given food, defined as the ratio of energy of the food to the weight of the food (kcal/g), is largely determined by water content, but is also affected by fat and fiber. Although the 2010 Dietary Guidelines encourage an eating pattern low in energy density (ED) to manage weight, it is currently not known what the best strategy is for reducing ED in the diet. Eating a greater number of foods low in ED or reducing the number of foods high in ED may reduce overall dietary ED. As ED is believed to reduce intake by allowing a greater weight of food relative to total energy consumed assisting with enhancing feelings of fullness, it is anticipated that either increasing consumption of low-ED foods in the diet alone or combining an increase in consumption of low-ED foods with a decrease in consumption of high-ED foods may be the best strategies for reducing overall dietary ED for weight loss.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Heart Condition, Major Psychiatric Diseases, Others
      Must Not Be Taking:Weight Loss Medication

      60 Participants Needed

      Meal Presentation for Energy Density

      Knoxville, Tennessee
      This study will investigate the energy consumed from an entree with high- or low-volume vegetables incorporated into the entree or served along side of the entree, in normal weight adults.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Binge Eating, Food Allergies, Smoking, Others
      Must Not Be Taking:Appetite Suppressants

      45 Participants Needed

      Snacking for Energy Intake in Preschoolers

      Knoxville, Tennessee
      The purpose of this pilot study will be to examine the influence of providing snacks on consumption of overall energy intake in children aged 2-5 years in the Early Learning Center (ELC) at the University of Tennessee.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:3 - 5

      Key Eligibility Criteria

      Disqualifiers:Food Allergies, Spoon Use, Attendance, Others

      20 Participants Needed

      Chewing Gum for Eating Habits

      Knoxville, Tennessee
      The purpose of this study is to examine if chewing gum before an eating bout will increase the rate of habituation and subsequently reduce energy intake within the eating bout.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 40

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Lactose Intolerance, Pregnancy, Others
      Must Not Be Taking:Appetite Suppressants

      20 Participants Needed

      Low-ED Diet vs Energy Balance Diet for Weight Loss Maintenance

      Knoxville, Tennessee
      A study to investigate the effect of a low-ED prescription (consume ≥10 foods ≤ 1.0 kcal/g and ≤ 2 foods ≥ 3.0 kcal/g per day) versus an energy balance prescription (consume a daily energy intake at estimated energy needs for maintenance) on weight loss maintenance.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Heart Condition, Joint Problems, Psychiatric Diseases, Bariatric Surgery, Others
      Must Not Be Taking:Weight Loss Drugs

      345 Participants Needed

      Grazing vs Three Meals a Day for Eating Habits

      Knoxville, Tennessee
      The purpose of this study is to examine the influence of two Eating Frequency prescriptions, meal (energy intake occurring during three meals per day) and grazing (energy intake occurring every two to three hours per day), on consumption during an ad libitum meal consumed at the end of the day, overall daily energy intake, and ratio of energy intake to energy expenditure. It is hypothesized that the grazing condition will produce lower consumption during an evening ad libitum meal, lower daily energy intake, and a lower ratio of energy intake to energy expenditure than the meal condition.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Bariatric Surgery, Pregnancy, Others
      Must Not Be Taking:Appetite Suppressants

      20 Participants Needed

      Portion Size Effects on Mood

      Knoxville, Tennessee
      The purpose of this study is to investigate whether different portion sizes will effect overall mood.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Athlete, Therapeutic Diet, Others
      Must Not Be Taking:Appetite Suppressants

      25 Participants Needed

      Eating Frequency for Weight Loss

      Knoxville, Tennessee
      The purpose of this study is to address the gap in knowledge regarding the relationship between eating frequency and weight loss.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Heart Condition, Diabetes, Bariatric Surgery, Others
      Must Not Be Taking:Weight Loss Medication

      30 Participants Needed

      Dietary Messages for Obesity

      Knoxville, Tennessee
      Examine the effect of three different dietary messages on dietary intake and the health of parents and their children.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:6 - 12

      Key Eligibility Criteria

      Disqualifiers:Dietary Restrictions, Physical Activity Restrictions, Pregnancy, Others

      45 Participants Needed

      Digital Monitoring App for Myasthenia Gravis

      Knoxville, Tennessee
      ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders. The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME\&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Thymectomy, Plasma Exchange, Immunoglobulin, Others

      144 Participants Needed

      Emraclidine for Renal Impairment

      Knoxville, Tennessee
      This trial is testing a medication called emraclidine to see how it behaves in people with different levels of kidney function. The study includes participants with mild, moderate, and severe kidney problems and compares them to those with normal kidney function. Researchers want to understand if kidney issues change how the body processes this drug.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      60 Participants Needed

      Apalutamide for Liver Disease

      Knoxville, Tennessee
      This trial is studying how a prostate cancer medication, apalutamide, is processed in the bodies of people with severe liver problems compared to those with normal liver function. The goal is to understand any differences in how the drug is absorbed, distributed, metabolized, and excreted between these two groups. Apalutamide is a next-generation androgen receptor inhibitor approved for treatment of subjects with high-risk, non-metastatic, castration-resistant prostate cancer (NM-CRPC).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      16 Participants Needed

      Pretomanid for Kidney Failure

      Knoxville, Tennessee
      This is a Phase 1, open-label, single-dose, sequential group study to compare the safety and pharmacokinetics (PK) of pretomanid in the following groups of participants: 1) participants with severe renal impairment including those with end stage renal disease (ESRD) not on dialysis, and participants with mild or moderate renal impairment, designated as Groups 2, 3, and 4, respectively; and 2) participants with normal renal function matched to the above renal impairment groups, designated as Groups 1A, 1B, and 1C, respectively. The study will be conducted following a reduced PK study design in Part A. Part A will enroll participants from Group 1A (i.e., 6 healthy matched controls) and Group 2 (i.e., 6 participants with severe renal impairment and ESRD, not on dialysis). A decision to proceed to Part B will be made after the PK of pretomanid, and safety in participants enrolled in Part A have been reviewed. If Part A demonstrates at least a 50% increase in pretomanid area under the plasma concentration-time curve (AUC) in Group 2 (severe renal impairments and ESRD, not on dialysis) relative to the exposures in Group 1A (matched participants with normal renal function), then the reduced PK study will extend to the full PK study to enroll participants into Part B (i.e., to investigate mild and moderate renal impairment). All Part B groups (1B, 1C, 3, and 4) will be enrolled concurrently. If the reduced PK study shows at least a 50% increase in AUC in patients with severe renal impairment and patients with ESRD not yet on dialysis relative to the matched healthy controls, a "full PK" renal impairment study in patients with all intermediate levels of renal function impairment should be conducted. Otherwise, no further study is recommended. The approximate patient involvement will be 3 months. The primary objective is to evaluate the PK profiles of pretomanid in plasma and urine after a single oral dose of 200 mg in participants with renal impairment compared to matched healthy controls.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      36 Participants Needed

      AV7909 Vaccine Booster for Anthrax

      Knoxville, Tennessee
      This trial tests the AV7909 vaccine on healthy adults aged 18-65 to see if it is safe and effective. The vaccine helps the body produce antibodies that can neutralize harmful substances. The AV7909 vaccine has shown to elicit a more robust immune response in older adults.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Schizophrenia, Others
      Must Not Be Taking:Herbal Medicines, Corticosteroids

      220 Participants Needed

      Zifibancimig for Age-Related Macular Degeneration

      Knoxville, Tennessee
      This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Vitrectomy, Glaucoma, Uveitis, Others
      Must Be Taking:Anti-VEGF

      251 Participants Needed

      Morpheus8 Radio Frequency Treatment for Axillary Hyperhidrosis

      Knoxville, Tennessee
      This trial tests a device that uses radio waves to treat people with excessive underarm sweating. The device works by heating and reducing the activity of sweat glands. Participants' progress will be monitored for several months.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Hypertension, Cancer, Others
      Must Not Be Taking:Anticoagulants, Isotretinoin, Anticholinergics, Cholinomimetics

      70 Participants Needed

      Pneumococcal Vaccine for Pneumonia Prevention

      Clyde, North Carolina
      This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:42 - 89

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Seizures, Bleeding Disorders, Others
      Must Not Be Taking:Immunosuppressants, Anticoagulants, Corticosteroids, Others

      2320 Participants Needed

      Why Other Patients Applied

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38
      Match to a Trial

      Chemotherapy + Immunotherapy for Acute Lymphoblastic Leukemia

      Clyde, North Carolina
      This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:30 - 70

      Key Eligibility Criteria

      Disqualifiers:Mature B ALL, Active Malignancy, Others
      Must Be Taking:Antiretrovirals

      488 Participants Needed

      Educational Website for Colorectal Cancer

      Corbin, Kentucky
      This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that aligns with current guidelines (guideline-concordant). Surveillance care after resection of colorectal cancer is critical to detect potentially curable return of disease (recurrence), yet up to 60% of colorectal cancer survivors fail to receive surveillance. This may be due to a lack of knowledge about the purpose of surveillance care and the risks of cancer recurrence, or a lack of confidence for managing surveillance care. The CTAC intervention is an online education intervention designed to improve patients' knowledge about surveillance and their self-efficacy for managing surveillance, and to promote effective communication with supporters and supporter engagement in patients' surveillance in a way that is aligned with each patient's preferences. By increasing a patient's knowledge, self-efficacy, and satisfaction with their supporter's engagement in their care, the CTAC intervention may increase the number of patients who receive guideline-concordant surveillance care after resection of colorectal cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Stage IV Cancer, Prior Malignancy, Others

      1057 Participants Needed

      Immunotherapy + Chemotherapy + Surgery +/- Radiation for Mesothelioma

      Corbin, Kentucky
      This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Diseases, Severe Infections, Cardiovascular Disease, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      28 Participants Needed

      Mobile Health for Breast Cancer

      Corbin, Kentucky
      This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:ECOG Status >= 3, Others
      Must Be Taking:CDK4/6 Inhibitors

      410 Participants Needed

      MOUD Pre-Treatment + Telehealth for Opioid Use Disorder

      Harlan, Kentucky
      This trial will test the effectiveness of delivering medication for opioid use disorder (MOUD) pre-treatment via telehealth, alone and with peer navigation, to increase MOUD initiation and maintenance in the community following jail release. This trial will focus on incarcerated women in 6 experimental and 3 control sites in Kentucky. Enrollment is not open to the general public.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment
      Must Be Taking:MOUD

      900 Participants Needed

      CRISPR CAR-T Cell Therapy for B-Cell Lymphoma

      Nashville, Tennessee
      CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Lymphoma, Seizure Disorder, Others
      Must Not Be Taking:Corticosteroids

      72 Participants Needed

      Early Detection Test for Cancer

      Asheville, North Carolina
      This trial is testing a new blood test called the GRAIL MCED test, which aims to detect multiple types of cancer early. GRAIL, a company formed by DNA-sequencing giant Illumina, is developing the GRAIL MCED test to detect multiple cancer types early. It targets people who are already recommended for cancer screening. The test works by looking for cancer-related DNA in the blood, and if found, further tests are done to confirm and locate the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Cancer Suspicion, Recent Cancer History, Pregnancy, Others

      35885 Participants Needed

      mRNA Vaccine for Flu

      Asheville, North Carolina
      The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Malignancy, Anaphylaxis, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressants, Antivirals, Others

      56000 Participants Needed

      9vHPV Vaccine for HPV-Related Oral Infections in Men

      Kingsport, Tennessee
      The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age. The primary hypothesis tested after the primary database lock is that administration of a 3-dose regimen of 9vHPV vaccine will reduce the incidence of human papillomavirus (HPV) 16/18/31/33/45/52/58-related oral persistent infection (6 months or longer) compared with placebo. There will also be an Extension Study to offer an opportunity to complete the 3 dose regimen of 9vHPV vaccine for participants who received placebo in the Base Study, or received less than 3 doses of 9vHPV vaccine in the Base Study.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:20 - 45
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Immunocompromised, Autoimmune Conditions, Drug Abuse, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, Chemotherapy, Others

      6033 Participants Needed

      Atorvastatin for Preventing Dementia

      Asheville, North Carolina
      PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:75+

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Dementia, ADL Dependence, Others
      Must Not Be Taking:Statins

      20000 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Knoxville, TN pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Knoxville, TN work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Knoxville, TN 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Knoxville, TN is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Knoxville, TN several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Knoxville, TN?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Knoxville, TN?

      Most recently, we added Health Communication + Support for COVID-19 Vaccine Hesitancy, MDMA for Liver Disease and MVA-BN Vaccine for Monkeypox to the Power online platform.